Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL

Although the tyrosine kinase inhibitor imatinib has been shown to be an active agent in patients with gastrointestinal stromal tumours (GIST), complete remissions are almost never seen and most patients finally experience disease progression during their course of treatment. An alternative therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Rikhof, B, van der Graaf, W T A, Meijer, C, Le, P T K, Meersma, G J, de Jong, S, Fletcher, J A, Suurmeijer, A J H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584951/
https://www.ncbi.nlm.nih.gov/pubmed/18941456
http://dx.doi.org/10.1038/sj.bjc.6604736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584951/
https://www.ncbi.nlm.nih.gov/pubmed/18941456
http://dx.doi.org/10.1038/sj.bjc.6604736

Ejemplares similares